Revance Therapeutics (NASDAQ:RVNC) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Revance Therapeutics (NASDAQ:RVNC) in a report issued on Saturday. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

A number of other brokerages have also recently issued reports on RVNC. Needham & Company LLC reaffirmed a “hold” rating on shares of Revance Therapeutics in a research note on Friday, January 17th. Barclays dropped their price objective on Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating for the company in a report on Monday, December 23rd. Nine analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $8.39.

Revance Therapeutics Stock Performance

Shares of NASDAQ:RVNC opened at $3.65 on Friday. Revance Therapeutics has a 1-year low of $2.30 and a 1-year high of $6.65. The stock has a market capitalization of $381.02 million, a P/E ratio of -1.89 and a beta of 0.90. The business has a 50-day moving average price of $3.65 and a two-hundred day moving average price of $3.89.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Natixis bought a new stake in Revance Therapeutics in the 4th quarter valued at $31,000. Two Sigma Securities LLC acquired a new position in shares of Revance Therapeutics during the fourth quarter worth about $35,000. Alpine Global Management LLC bought a new position in shares of Revance Therapeutics during the fourth quarter worth about $37,000. RPO LLC acquired a new stake in Revance Therapeutics in the 4th quarter valued at approximately $55,000. Finally, Fairfax Financial Holdings Ltd. Can bought a new stake in Revance Therapeutics in the 4th quarter valued at approximately $64,000. Institutional investors and hedge funds own 97.70% of the company’s stock.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.